文献速递胸部肿瘤

索托拉西布(960 mg或240 mg)每日一次治疗既往经治的KRAS G12C突变晚期非小细胞肺癌

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
PubMed 文献 · Eur J Cancer · 2024-07-05

这项2期随机开放标签研究将既往经治的KRAS G12C突变晚期非小细胞肺癌患者分配至索托拉西布960 mg组(n=104)或240 mg组(n=105),每日一次口服。960 mg组客观缓解率为32.7%,240 mg组为24.8%;中位无进展生存期分别为5.4个月和5.6个月,中位总生存期分别为13.0个月和11.7个月。该描述性分析中960 mg组客观缓解率、疾病控制率、缓解持续时间和总生存期数值上高于240 mg组,治疗中出现的不良事件可通过说明书指导的剂量调整进行管理。

要点

  • 960 mg组(n=104)客观缓解率32.7%、疾病控制率86.5%;240 mg组(n=105)分别为24.8%、81.9%。
  • 中位无进展生存期960 mg组5.4个月 vs 240 mg组5.6个月;中位随访17.5个月时中位总生存期13.0个月 vs 11.7个月。
  • 960 mg组AUC0-24h和Cmax数值上为240 mg组的1.3倍;常见治疗中出现的不良事件包括腹泻、恶心、丙氨酸氨基转移酶升高和天冬氨酸氨基转移酶升高。

核心结论

  • 在这项描述性分析中,接受索托拉西布960 mg每日一次治疗的患者客观缓解率和疾病控制率数值上高于240 mg组,缓解持续时间和总生存期也更长。
  • 治疗中出现的不良事件可通过说明书指导的剂量调整进行管理。

研究设计与样本

  • 2期、随机、开放标签研究,成人KRAS G12C突变晚期非小细胞肺癌患者接受索托拉西布960 mg或240 mg每日一次口服。
  • 960 mg组n=104,240 mg组n=105。
  • 主要终点为客观缓解率和安全性;次要终点包括疾病控制率、无进展生存期、总生存期和药代动力学。
  • 该研究未针对正式统计假设检验进行功效计算。
  • 临床试验注册号NCT03600883。

主要发现

  • 960 mg组(n=104)客观缓解率32.7%,疾病控制率86.5%;240 mg组(n=105)客观缓解率24.8%,疾病控制率81.9%。
  • 中位无进展生存期960 mg组5.4个月 vs 240 mg组5.6个月。
  • 中位随访17.5个月时,中位总生存期960 mg组13.0个月 vs 240 mg组11.7个月。
  • 960 mg剂量下AUC0-24h和Cmax数值上为240 mg组的1.3倍。
  • 治疗中出现的不良事件(≥10%)在960 mg组和240 mg组分别为:腹泻39.4%和31.7%,恶心23.1%和19.2%,丙氨酸氨基转移酶升高14.4%和17.3%,天冬氨酸氨基转移酶升高13.5%和13.5%。

关键数值与推荐

  • 960 mg组客观缓解率32.7%,240 mg组24.8%。
  • 960 mg组疾病控制率86.5%,240 mg组81.9%。
  • 960 mg组中位无进展生存期5.4个月,240 mg组5.6个月。
  • 960 mg组中位总生存期13.0个月,240 mg组11.7个月,中位随访17.5个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该研究未针对正式统计假设检验进行功效计算。
  • 结论基于描述性分析,原文将960 mg组与240 mg组之间的差异表述为数值上更高或更长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at lower doses; therefore, we evaluated the efficacy and safety of sotorasib 960 mg and 240 mg. METHODS: In this phase 2, randomized, open-label study, adults with KRAS G12C-mutated advanced NSCLC received sotorasib 960 mg or 240 mg once daily. Primary endpoints were objective response rate (ORR) and safety. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and pharmacokinetics. The study was not powered for formal statistical hypothesis testing. RESULTS: In the 960 mg group (n = 104), ORR was 32.7 % and DCR was 86.5 %. In the 240 mg group (n = 105), ORR was 24.8 % and DCR was 81.9 %. Median PFS was 5.4 months (960 mg) and 5.6 months (240 mg). At a median follow-up of 17.5 months, median OS was 13.0 months (960 mg) and 11.7 months (240 mg). AUC0-24 h and Cmax were 1.3-fold numerically higher with the 960 mg dose. Treatment-emergent adverse events (TEAEs, ≥10 %) for 960 mg and 240 mg doses, respectively, were diarrhea (39.4 %; 31.7 %), nausea (23.1 %; 19.2 %), increased alanine aminotransaminase (14.4 %; 17.3 %), and increased aspartate aminotransferase (13.5 %; 13.5 %). CONCLUSIONS: Patients treated with sotorasib 960 mg once daily had numerically higher ORR and DCR, and longer DOR and OS, than patients treated with 240 mg in this descriptive analysis. TEAEs were manageable with label-directed dose modifications. CLINICAL TRIAL REGISTRATION: NCT03600883.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hochmair MJ, Vermaelen K, Mountzios G, et al. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. Eur J Cancer. 2024. PMID: 39029295. doi:10.1016/j.ejca.2024.114204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。